Withus Pharmaceutical Co

Withus Pharmaceutical Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Withus Pharmaceutical Co (330350.KQ) as of Nov 1, 2026 is 73.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 64.11 % — a change of 15.15% (higher).

FCF Conversion

73.82 %

YoY

15.15%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Withus Pharmaceutical Co is 2025 73.82 % . FCF Conversion Rate (FCF/EBITDA) of Withus Pharmaceutical Co was 2024 64.11 % . It decreases by 15.15% higher compared to the previous year.

The Withus Pharmaceutical Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
55.46 KRW
Jan 1, 2019
40.51 KRW
Jan 1, 2020
-238.54 KRW
Jan 1, 2021
31.76 KRW
Jan 1, 2022
-401.44 KRW
Jan 1, 2023
-166.33 KRW
Jan 1, 2024
64.11 KRW
Jan 1, 2025
73.82 KRW
The Withus Pharmaceutical Co FCF Conversion history
YEARFCF ConversionYoY
73.82 %+15.15%
64.11 %-138.54%
-166.33 %-58.57%
-401.44 %-1,363.86%
31.76 %-113.32%
-238.54 %-688.88%
40.51 %-26.96%
55.46 %+10.79%
50.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co Stock analysis

What does Withus Pharmaceutical Co do? Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution. Withus Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Withus Pharmaceutical Co stock

FCF Conversion Rate (FCF/EBITDA) of Withus Pharmaceutical Co is 73.82 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Withus Pharmaceutical Co changed from 64.11 % to 73.82 %, representing a 15.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Withus Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Withus Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Withus Pharmaceutical Co

All Key Metrics — Withus Pharmaceutical Co